Related Experiment Video
Updated: Feb 10, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Irritable bowel syndrome with diarrhea: time to change practice?
Cristina Caranfil1,2, Luisa Bertin1,2, Fabiana Zingone1,2
1Department of Surgery, Oncology and Gastroenterology, University of Padua.
Contemporary evidence supports shifting irritable bowel syndrome with diarrhea (IBS-D) diagnosis and treatment. Focus is now on targeted investigations and mechanism-based therapies, including neuromodulators and dietary changes, for better patient outcomes.
Area of Science:
- Gastroenterology
- Neuroimmunology
- Clinical Practice Guidelines
Background:
- Traditional irritable bowel syndrome with diarrhea (IBS-D) management involved extensive exclusionary testing and empirical symptom control.
- Recent advancements in neuroimmune pathophysiology, diagnostics, biomarkers, and treatment efficacy necessitate a re-evaluation of current IBS-D practices.
Purpose of the Study:
- To evaluate if accumulated evidence warrants significant changes in contemporary diagnostic and therapeutic practices for IBS-D.
- To assess the impact of new understanding in neuroimmune pathways and novel biomarkers on IBS-D management.
Main Methods:
- Review of recent systematic reviews and emerging evidence on diagnostic algorithms and treatment efficacy.
- Analysis of novel biomarkers and their potential role in IBS-D diagnosis.
- Evaluation of therapeutic strategies including neuromodulators, dietary interventions, and behavioral therapies.
Main Results:
- Diagnostic approaches are shifting towards symptom-based strategies with targeted testing for specific conditions.
- Emerging biomarkers like neutrophil-to-albumin ratio and microRNA-148 show diagnostic potential.
- Effective treatments include tricyclic antidepressants, low FODMAP and Mediterranean diets, and brain-gut behavioral therapies.
Conclusions:
- Evidence supports a shift from exclusionary testing to targeted investigations of treatable conditions.
- Mechanism-based multimodal interventions integrating neuromodulators, diet, and behavioral therapies are recommended.
- Individualized treatment selection based on phenotype and comorbidities, delivered via integrated care models, is crucial for optimal IBS-D management.
Related Concept Videos
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
Global Climate Change
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Rates of Change

